Willauer Alexandra N, Sherman Kenneth E
Department of Medicine, Division of Gastroenterology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Massachusetts General Hospital, 15 Parkman Street Wang Ambulatory Care Center- 5, 02114, Boston, MA, USA.
Curr HIV/AIDS Rep. 2025 Sep 15;22(1):45. doi: 10.1007/s11904-025-00754-z.
Liver biopsy and FNA in persons with HIV-HBV coinfection can aid in the assessment of intrahepatic milieu, direct functional cure strategies, and facilitate development of novel therapeutics.
Liver tissue sampling provides important insight into the intrahepatic viral reservoir and complex immune microenvironment in HIV-HBV coinfection. Additionally, the development of tissue-based viral markers, specifically cccDNA and integrated HBV DNA, paired with novel, noninvasive biomarkers and advanced techniques for tissue processing and analysis have been instrumental in this process. Hepatic tissue sampling also offers unique insights into treatment responses and understanding deficiencies of existing therapies that cannot be assessed by noninvasive means alone, which informs the development of novel therapeutics. Liver biopsy and liver tissue fine needle aspiration represent important modalities that will continue to drive research and innovation leading to HBV cure strategies.
对合并感染HIV和HBV的患者进行肝活检和细针穿刺抽吸有助于评估肝内环境、指导功能性治愈策略并促进新型疗法的开发。
肝组织采样为合并感染HIV和HBV患者的肝内病毒储存库及复杂免疫微环境提供了重要见解。此外，基于组织的病毒标志物，特别是共价闭合环状DNA（cccDNA）和整合型HBV DNA的开发，与新型非侵入性生物标志物以及先进的组织处理和分析技术相结合，在这一过程中发挥了重要作用。肝组织采样还为治疗反应以及理解现有疗法无法仅通过非侵入性手段评估的不足之处提供了独特见解，这为新型疗法的开发提供了依据。肝活检和肝组织细针穿刺抽吸是重要的方式，将继续推动导致HBV治愈策略的研究和创新。
